Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients
Clinical trial NCT06403709 · UNKNOWN
Trial details
- NCT number
- NCT06403709
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-01
- Primary completion
- 2024-08-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.